title: Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
abstract: BACKGROUND
  The 17p13.1 deletion that causes loss of the p53-encoding TP53 gene is the most powerful predictor of a poor response to conventional therapy and shortened survival in patients with chronic lymphocytic leukemia (CLL). The results of this study have demonstrated that the cladribine and cyclophosphamide regimen may improve treatment results in this poor-risk patient population.
  
  
  METHODS
  In this study, the authors retrospectively analyzed the efficacy and toxicity of 2-CdA with cyclophosphamide combination (the CC regimen) in 20 patients with previously untreated B-cell CLL who had 17p13.1 deletion reported to the Polish Adult Leukemia Group (PALG) registry. The CC regimen consisted of 2-CdA at a dose of 0.12 mg/kg and cyclophosphamide at a dose of 250 mg/m2 given intravenously for 3 consecutive days. The CC cycles were repeated at 28-day intervals for up to 6 cycles.
  
  
  RESULTS
  Overall, 16 of 20 patients (80%) responded to CC therapy, including 10 patients (50%) who obtained a complete response and 6 patients (30%) who obtained a partial response. The median progression-free survival reached 23 months (95% confidence interval, 5-41 months). The overall survival probability at 2 years was 52.5% (95% confidence interval, 26%-79%). Treatment toxicity generally was acceptable. Infections were the most common grade 3/4 complications and occurred in 6 patients (30%).
  
  
  CONCLUSIONS
  In this retrospective analysis, the results demonstrated that the CC regimen produced a relatively high response rate in patients with previously untreated CLL who had 17p13.1/TP53 deletion, although the response duration and survival were not satisfactory. It is possible that a combination of the CC regimen with p53-independent agents may improve treatment results in this poor-risk patient population.
authors.affiliation: Department of Hematology, Medical University of Lodz, Lodz, Poland. robaktad@csk.umed.lodz.pl
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.forename: Jerzy Z
authors.initials: JZ
authors.lastname: Blonski
authors.forename: Ewa
authors.initials: E
authors.lastname: Wawrzyniak
authors.forename: Joanna
authors.initials: J
authors.lastname: Gora-Tybor
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Palacz
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszynska
authors.forename: Lech
authors.initials: L
authors.lastname: Konopka
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Jamroziak
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002886:Chromosomes, Human, Pair 17; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D016158:Genes, p53; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017384:Sequence Deletion
chemical_list: D017338:Cladribine; D003520:Cyclophosphamide